As part of its mandate, the SGC has developed multiple strategies for the recombinant expression, purification, crystallization and biophysical and biochemical characterization of human and protozoan proteins. The SGC has decided to focus itís science on three strategic areas:
ē Create partnerships to generate selective probes for SGC targets (e.g. antibody and small molecule)
ē Membrane protein structural biology
ē Develop oncology program focused on the full complement of human kinases (kinome)
To facilitate screening for small molecules that bind and stabilize proteins, thereby promoting crystallization, the SGC has implemented two screening platforms based fluorimetry or static light scattering. Its small molecule libraries consist of bioactive compounds such as nucleotides, cofactors, substrates and inhibitors, as well as FDA-approved drugs and drug-like compounds.